Corporate | 9 December 2016 07:00
Carl Zeiss Meditec AG continues its growth trend
|
DGAP-News: Carl Zeiss Meditec AG / Key word(s): Final Results
Carl Zeiss Meditec AG continues its growth trend
JENA, 9 December 2016 Carl Zeiss Meditec AG has brought financial year 2015/16 to a successful close with further growth: Revenue increased by 4.6 percent (adjusted for currency effects: 2.7 percent) to EUR1,088.4m. Earnings before interest and taxes (EBIT) rose to EUR154.3m (prior year: EUR130.6m). The EBIT margin increased to 14.2 percent (prior year: 12.6 percent). Earnings per share reached EUR1.21 (prior year: EUR0.77). Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG looks back on the past fiscal year with satisfaction: “We have achieved profitable growth and met our forecast revenue range of EUR1,080 – EUR1,120m. We have also gained additional market share, particularly in Ophthalmology. The trend in recurring revenue is also positive – as much as 32% of our business is attributable to consumables for cataract and refractive surgery, service revenue and other recurring sources of revenue. The new organizational structure announced in July 2016 will help us to offer our customers an even better service and to seize additional opportunities for growth.” Strongest growth in Ophthalmic Systems SBU Both Ophthalmology business units achieved growth: revenue in the Ophthalmic Systems SBU (OPH) increased by 7.5 percent in the fiscal year, to EUR421.2m, compared with EUR392.0m in the same period of the prior year. Adjusted for currency effects, revenue increased by 5.2 percent. The business with laser systems for refractive vision correction developed particularly well. The Surgical Ophthalmology SBU (SUR) increased its revenue by 4.3 percent (adjusted for currency effects: 2.9 percent) to EUR370.7m (prior year: EUR355.3m). Significant increases were once again achieved by intraocular lenses for treating cataracts. Under the new SBU structure, the combined SBU Ophthalmic Devices would have grown revenue to EUR791.9m – an increase of 6.0 percent (4.1 percent adjusted for currency effects). Revenue growth in the Microsurgery SBU was 1.3 percent and was boosted by positive currency effects. Revenue from surgical microscopes and visualization solutions climbed to EUR296.5m, compared with EUR292.8m in the prior year. The development of business in the Japanese market was particularly restrained. Adjusted for currency effects, revenue was down by -0.9%, thus remaining slightly below the level of a year ago. Asia/Pacific becomes largest reporting region After another strong performance by Asia/Pacific, this reporting region has become the largest segment for the first time. At EUR381.7m, revenue was significantly higher than the prior-year figure of EUR319.4m – an increase of 19.5 percent. Adjusted for currency effects, this growth would still have amounted to 15.5 percent. A large part of this growth is attributable to the Chinese market, as well as Southeast Asia and South Korea. Revenue in the EMEA region declined slightly, by 1.7 percent to EUR352.7m (prior year: EUR358.8m). Germany, France and the United Kingdom made good contributions to revenue Business in Southern Europe and the Middle East declined.
Revenue in the Americas region decreased by 2.2 percent to EUR354.0m (prior year: EUR361.9m). The strength of the US dollar had a positive effect in this region.
Earnings per share (EPS) increased significantly year-on-year, to EUR1.21 (prior year: EUR0.77). The increase in operating profit contributed to this – the prior year was also affected significantly by extraordinary expenses arising from a financial interest. Carl Zeiss Meditec AG has set itself the target to continue growing at least the same rate as the underlying market in fiscal year 2016/17. The EBIT margin is expected to continue to move within the range also forecast for the medium term, of 13-15%. Revenue by strategic business unit
Revenue by region
Contact for media and investors
Brief profile
The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company’s presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world’s leading companies in the optical and optoelectronic industries. For more information visit our website at: www.zeiss.com/meditec-ag/
2016-12-09 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
|
| Language: | English | |
| Company: | Carl Zeiss Meditec AG | |
| Göschwitzer Str. 51-52 | ||
| 07745 Jena | ||
| Germany | ||
| Phone: | +49 (0)3641 220-0 | |
| Fax: | +49 (0)3641 220-112 | |
| E-mail: | investors.meditec@zeiss.com,info.meditec@zeiss.com | |
| Internet: | www.meditec.zeiss.de | |
| ISIN: | DE0005313704 | |
| WKN: | 531370 | |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange | |
| End of News | DGAP News Service |